2 January 2014
Smiths Medical has gained a key US Food and Drug Administration (FDA) approval for a customisable infusion system that helps maintain effective epidural analgesia during labour and delivery or with post-operative pain management.
The FDA 510(k) clearance allows Smiths Medical to market its CADD®-Solis pain management system version 3.0 with Programmed Intermittent Bolus (PIB) and Patient Controlled Analgesics (PCA) delivery in the United States.
PIB medication delivery, using the CADD®-Solis v3.0, consistently administers programmed intermittent boluses (doses) that can be supplemented by the patient, improving pain relief and reducing the need for clinical interventions.
The CADD®-Solis ambulatory infusion system, designed for nurses, anesthesiologists, pharmacists and other hospital personnel, is a state-of-the-art system that meets industry recognised standards for advanced error-reduction features in PCA pumps.
Related articles
Smiths Interconnect launches new technology to improve connectivity in mission critical applications
Read our latest company news as Smiths Interconnect launches new connector technology
Find out moreSmiths Group supports launch of Ariane 6 space rocket
Read our latest company news as Smiths Group supports the launch of the Ariane 6 space rocket
Find out moreSmiths Detection Selected by Zurich Airport to Trial Advances CT X-Ray Scanners
Read our latest company news as Smiths Detection is selected by by Zurich Airport to Trial Advances CT X-Ray Scanners.
Find out more